We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: bispecific antibody
MedXY News
EnglishTag

bispecific antibody

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Innovative CD38-Targeted Bispecific Antibody XmAb18968 Shows Promise in Relapsed/Refractory AML and T-ALL
Hematology-Oncologybispecific antibodyT-cell acute lymphoblastic leukemia

Innovative CD38-Targeted Bispecific Antibody XmAb18968 Shows Promise in Relapsed/Refractory AML and T-ALL

By MedXY|Sep 18, 2026

A phase 1 trial of XmAb18968, a CD38-CD3 bispecific antibody, demonstrates safety and encouraging efficacy in heavily pretreated relapsed/refractory AML and T-ALL patients, highlighting a novel therapeutic avenue.

Epcoritamab Monotherapy Demonstrates Potent Antitumor Activity in Richter Transformation: Insights from EPCORE CLL-1
Hematology-Oncologybispecific antibodyEpcoritamab
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story

Epcoritamab Monotherapy Demonstrates Potent Antitumor Activity in Richter Transformation: Insights from EPCORE CLL-1

By MedXY|Jan 16, 2026

The EPCORE CLL-1 trial evaluated epcoritamab, a CD3×CD20 bispecific antibody, in patients with Richter transformation. While the 47.6% overall response rate narrowly missed the 50% target, the results highlight a significant therapeutic sig

Moving Beyond Injectables: SOR102 Shows Promise as an Oral Dual-Inhibitor for Ulcerative Colitis
Gastroenterologybispecific antibodyulcerative colitis

Moving Beyond Injectables: SOR102 Shows Promise as an Oral Dual-Inhibitor for Ulcerative Colitis

By MedXY|Dec 20, 2025

A Phase 1 trial of SOR102, a first-in-class oral bispecific antibody targeting TNF and IL-23, demonstrates favorable safety and preliminary clinical activity in patients with ulcerative colitis, suggesting a potential shift toward localized

Hematology-Oncologybispecific antibodyimmunotherapy

Comprehensive Summary of Talquetamab Monotherapy and Combination Therapy in Relapsed or Refractory Multiple Myeloma

By MedXY|Dec 19, 2025

Talquetamab, alone or combined with teclistamab, shows promising efficacy in treating relapsed/refractory multiple myeloma, including extramedullary disease, though high-grade adverse events are common but manageable.

Ivonescimab (PD‑1/VEGF bispecific) Plus Chemo Outperforms PD‑1+Chemo in First‑Line Advanced Squamous NSCLC: HARMONi‑6 Results Redefine a Tough Indication
newsbispecific antibody

Ivonescimab (PD‑1/VEGF bispecific) Plus Chemo Outperforms PD‑1+Chemo in First‑Line Advanced Squamous NSCLC: HARMONi‑6 Results Redefine a Tough Indication

By MedXY|Nov 2, 2025

Phase 3 HARMONi‑6: ivonescimab + paclitaxel/carboplatin increased median PFS to 11.1 vs 6.9 months (HR 0.60, P<0.0001) and improved ORR versus tislelizumab+chemo in first‑line advanced squamous NSCLC, with low major bleeding (≥ grade 3,

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities